Targeted inhibition of a "signal jammer" protein may improve how tumors respond to immunotherapy. Published today in Nature, ...

BASEL, Switzerland, March 20, 2025 /PRNewswire/ -- Versameb AG ("Versameb"), a clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the ...

Get Instant Summarized Text (Gist) Inhibiting the protein VDAC2 enhances tumor response to immunotherapy by preventing it from acting as a "signal jammer" that blocks immune communication. This ...